NASDAQ:MRNA

Moderna (MRNA) Stock Forecast, Price & News

$125.61

-1.29 (-1.02%)

(As of 06/7/2023 ET)

Compare

Today's Range: $125.30
▼
$127.09
50-Day Range: $125.11
▼
$160.53
52-Week Range: $115.03
▼
$217.25

Volume: 3.16 million shs
Average Volume: 3.05 million shs
Market Capitalization: $47.88 billion

P/E Ratio: 10.86
Dividend Yield: N/A
Price Target: $179.13

Moderna MarketRank™ Forecast

Analyst Rating: Hold
2.36 Rating Score
Upside/Downside: 42.6% Upside
$179.13 Price Target
Short Interest: Bearish
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.71
Upright™ Environmental Score
News Sentiment: -0.13
Based on 21 Articles This Week
Insider Trading: Selling Shares
$64.78 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.84) to ($3.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

307th out of 981 stocks

Biological Products, Except Diagnostic Industry

45th out of 159 stocks

3.2

Analyst's Opinion

Consensus Rating
Moderna has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 7 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $179.13, Moderna has a forecasted upside of 42.6% from its current price of $125.61.
Amount of Analyst Coverage
Moderna has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Moderna has been sold short.
Short Interest Ratio / Days to Cover
Moderna has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Moderna has recently increased by 2.07%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Moderna does not currently pay a dividend.
Dividend Growth
Moderna does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Moderna has received a 72.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "mRNA vaccines", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Moderna is -2.71.

1.0

News and Social Media Coverage

News Sentiment
Moderna has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 21 news articles for Moderna this week, compared to 13 articles on an average week.
Search Interest
Only 57 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
Only 16 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,777,550.00 in company stock.
Percentage Held by Insiders
15.70% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.11% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Moderna are expected to decrease in the coming year, from ($2.84) to ($3.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Moderna is 10.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.84.
Price to Earnings Ratio vs. Sector
The P/E ratio of Moderna is 10.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.21.
Price to Book Value per Share Ratio
Moderna has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Moderna (NASDAQ:MRNA) Stock

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

MRNA Stock News Headlines

May 18, 2023 | marketbeat.com

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (MRNA)

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

May 18, 2023 | marketbeat.com

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (MRNA)

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

June 8, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

June 7, 2023 | finance.yahoo.com

Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement

June 7, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Sell Rating on Moderna (MRNA)

June 7, 2023 | finance.yahoo.com

Those who invested in Moderna (NASDAQ:MRNA) three years ago are up 118%

June 7, 2023 | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 110 Shares

June 7, 2023 | americanbankingnews.com

Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells 309 Shares of Stock

June 8, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.

June 7, 2023 | msn.com

Moderna, Pfizer sued over technology developed by Scripps researchers that made COVID-19 vaccine possible

June 6, 2023 | msn.com

Moderna Unusual Options Activity For June 06

June 6, 2023 | seekingalpha.com

Moderna, Inc. (MRNA) ASCO Investor Event Conference (Transcript)

June 5, 2023 | msn.com

How To Detect Under The Radar Plays - $AMD $NKE $MRNA $H $BEEM - Daily Stocks To Watch

June 5, 2023 | msn.com

Moderna and Merck reveal new data on individualized cancer treatment

June 3, 2023 | finance.yahoo.com

Recent uptick might appease Moderna, Inc. (NASDAQ:MRNA) institutional owners after losing 4.8% over the past year

June 3, 2023 | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

June 3, 2023 | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel Sells 40,000 Shares of Stock

June 1, 2023 | finanznachrichten.de

Moderna, Inc.: Moderna to Present at Upcoming Conferences in June 2023

June 1, 2023 | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 1,181 Shares of Stock

May 30, 2023 | bizjournals.com

Moderna buys biomanufacturing site in Marlborough for $91M

May 30, 2023 | bizjournals.com

Moderna gets $3.1M tax break for Norwood jobs; 42 other Mass. incentives announced

May 30, 2023 | msn.com

If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today

May 29, 2023 | americanbankingnews.com

Stephane Bancel Sells 40,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

May 26, 2023 | msn.com

Unusual Put Option Trade in Moderna (MRNA) Worth $18,396.00K

May 26, 2023 | msn.com

mRNA Vaccines Protect Against COVID-19 Mortality, Contrary to Misleading Posts

May 26, 2023 | reuters.com

Moderna looks for opportunities in China after registering legal entity

May 25, 2023 | news.yahoo.com

After Covid-19, can mRNA vaccines help with cancer as well?

See More Headlines

MRNA Price History

30 days | 90 days | 365 days | Advanced Chart

MRNA Company Calendar

Last Earnings: 5/04/2023
Today: 6/07/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRNA
CUSIP: N/A
CIK: 1682852
Web: www.modernatx.com
Phone: (617) 714-6500
Fax: N/A
Employees: 3,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $179.13
High Stock Price Forecast: $296.00
Low Stock Price Forecast: $93.00
Forecasted Upside/Downside: +42.6%
Consensus Rating: Hold
Rating Score (0-4): 2.36
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $11.57
Trailing P/E Ratio: 10.86
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $8.36 billion
Net Margins: 31.77%
Pretax Margin: 33.47%
Return on Equity: 25.87%
Return on Assets: 18.75%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 3.46
Quick Ratio: 3.26

Sales & Book Value

Annual Sales: $19.26 billion
Price / Sales: 2.49
Cash Flow: $22.15 per share
Price / Cash Flow: 5.67
Book Value: $49.78 per share
Price / Book: 2.52

Miscellaneous

Outstanding Shares: 381,210,000
Free Float: 321,359,000
Market Cap: $47.88 billion
Optionable: Optionable
Beta: 1.70

Social Links

Key Executives

Stéphane Bancel
Chief Executive Officer & Director

Stephen Hoge
President

James M. Mock
Chief Financial Officer

Paul Burton
Chief Medical Officer

Jerh Collins
Chief Technical Operations & Quality Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRNA Stock - Frequently Asked Questions

Should I buy or sell Moderna stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.
What is Moderna's stock price forecast for 2023?: 14 Wall Street research analysts have issued 1-year target prices for Moderna's shares. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they predict the company's share price to reach $179.13 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.
How have MRNA shares performed in 2023?: Moderna's stock was trading at $179.62 at the beginning of the year. Since then, MRNA shares have decreased by 30.1% and is now trading at $125.61.
View the best growth stocks for 2023 here.
When is Moderna's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MRNA earnings forecast.
How were Moderna's earnings last quarter?: Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, May, 4th. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of ($1.77) by $1.96. The company had revenue of $1.86 billion for the quarter, compared to analysts' expectations of $1.17 billion. Moderna had a trailing twelve-month return on equity of 25.87% and a net margin of 31.77%. The business's revenue was down 69.3% on a year-over-year basis. During the same period in the previous year, the business posted $8.58 earnings per share.
What ETFs hold Moderna's stock?: ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Direxion mRNA ETF (MSGR), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Genomics Immunology and Healthcare ETF (IDNA) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).
What is Stéphane Bancel's approval rating as Moderna's CEO?: 57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Moderna own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?: (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.
What is Moderna's stock symbol?: Moderna trades on the NASDAQ under the ticker symbol "MRNA."
Who are Moderna's major shareholders?: Moderna's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (12.03%), BlackRock Inc. (6.58%), State Street Corp (3.69%), Geode Capital Management LLC (1.64%), Wellington Management Group LLP (1.13%) and FMR LLC (1.04%). Insiders that own company stock include David W Meline, Dustin A Moskovitz, Elizabeth G Nabel, Juan Andres, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.
How do I buy shares of Moderna?: Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Moderna's stock price today?: One share of MRNA stock can currently be purchased for approximately $125.61.
How much money does Moderna make?: Moderna (NASDAQ:MRNA) has a market capitalization of $47.88 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $11.57 on an earnings per share basis.
How many employees does Moderna have?: The company employs 3,900 workers across the globe.
How can I contact Moderna?: Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.

This page (NASDAQ:MRNA) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial